AR101304A1 - Métodos para conjugar un agente con una mitad tiol en una proteína que contiene al menos un enlace trisulfuro - Google Patents

Métodos para conjugar un agente con una mitad tiol en una proteína que contiene al menos un enlace trisulfuro

Info

Publication number
AR101304A1
AR101304A1 ARP150102358A ARP150102358A AR101304A1 AR 101304 A1 AR101304 A1 AR 101304A1 AR P150102358 A ARP150102358 A AR P150102358A AR P150102358 A ARP150102358 A AR P150102358A AR 101304 A1 AR101304 A1 AR 101304A1
Authority
AR
Argentina
Prior art keywords
protein
agent
trisulfide
conjug
methods
Prior art date
Application number
ARP150102358A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR101304A1 publication Critical patent/AR101304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP150102358A 2014-07-24 2015-07-24 Métodos para conjugar un agente con una mitad tiol en una proteína que contiene al menos un enlace trisulfuro AR101304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028679P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
AR101304A1 true AR101304A1 (es) 2016-12-07

Family

ID=55163580

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102358A AR101304A1 (es) 2014-07-24 2015-07-24 Métodos para conjugar un agente con una mitad tiol en una proteína que contiene al menos un enlace trisulfuro

Country Status (15)

Country Link
US (2) US11370838B2 (enExample)
EP (1) EP3172219A4 (enExample)
JP (3) JP6956630B2 (enExample)
KR (1) KR102463267B1 (enExample)
CN (1) CN106536540A (enExample)
AR (1) AR101304A1 (enExample)
AU (2) AU2015294389B2 (enExample)
BR (1) BR112017001403A2 (enExample)
CA (1) CA2955007C (enExample)
IL (1) IL250148B2 (enExample)
MX (2) MX2017001022A (enExample)
MY (1) MY198629A (enExample)
RU (2) RU2021106673A (enExample)
SG (2) SG10202102467RA (enExample)
WO (1) WO2016014360A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102463267B1 (ko) * 2014-07-24 2022-11-03 제넨테크, 인크. 적어도 하나의 트리설파이드 결합을 함유하는 단백질에서 티올 모이어티에 제제의 접합 방법
RU2759602C2 (ru) * 2017-02-08 2021-11-16 Пфайзер Инк. Процесс крупномасштабного производства кэпированных и некэпированных цистеинов антител и их применение для конъюгации терапевтических белков

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2665353B2 (ja) * 1988-09-10 1997-10-22 住商ファーマインターナショナル株式会社 双特異性抗体の製造法
JPH0278699A (ja) 1988-09-12 1990-03-19 Green Cross Corp:The ベンゾイルウレア系化合物・アルブミン複合体
JPH02218700A (ja) * 1989-02-17 1990-08-31 Nippon Kayaku Co Ltd 双特異性抗体及びそれを用いる養子免疫療法
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ZA955789B (en) 1994-07-15 1996-03-11 Novo Nordisk As A method of converting a hydrophobic derivative of a polypeptide into the native form
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11124395A (ja) 1997-10-16 1999-05-11 Seiwa Kasei Kk システイン導入ペプチドおよびその製造方法
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
CA2374050A1 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
WO2002062827A2 (en) 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
CA2558399C (en) * 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ATE463503T1 (de) * 2004-12-29 2010-04-15 Novo Nordisk Healthcare Ag Verfahren zur verhinderung der bildung von trisulfidderivaten von polypeptiden
WO2007140371A2 (en) * 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
JP5394246B2 (ja) 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
TW200902554A (en) * 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
MX2010008310A (es) * 2008-01-31 2010-12-21 Georgia Pacific Chemicals Llc Composicion oxidada y maleatada modificada.
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2483289B2 (en) * 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
EP2542576B1 (en) * 2010-03-02 2016-04-20 Seattle Genetics, Inc. Methods for screening antibodies
WO2012059873A2 (en) * 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
US9562252B2 (en) * 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
EP3539982B1 (en) * 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
BR112014027166A2 (pt) * 2012-05-01 2017-06-27 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates
KR102463267B1 (ko) 2014-07-24 2022-11-03 제넨테크, 인크. 적어도 하나의 트리설파이드 결합을 함유하는 단백질에서 티올 모이어티에 제제의 접합 방법

Also Published As

Publication number Publication date
BR112017001403A2 (pt) 2017-11-21
US11370838B2 (en) 2022-06-28
KR102463267B1 (ko) 2022-11-03
JP2017526652A (ja) 2017-09-14
AU2015294389A1 (en) 2017-02-23
JP2023052645A (ja) 2023-04-11
JP7219256B2 (ja) 2023-02-07
SG11201700365TA (en) 2017-02-27
SG10202102467RA (en) 2021-04-29
RU2017105428A3 (enExample) 2018-08-29
US20220372141A1 (en) 2022-11-24
IL250148A0 (en) 2017-03-30
MX2022012589A (es) 2022-11-09
IL250148B2 (en) 2023-03-01
CA2955007A1 (en) 2016-01-28
EP3172219A1 (en) 2017-05-31
MX2017001022A (es) 2017-12-20
JP2021046419A (ja) 2021-03-25
JP6956630B2 (ja) 2021-11-02
RU2017105428A (ru) 2018-08-29
MY198629A (en) 2023-09-11
RU2744978C2 (ru) 2021-03-17
AU2015294389B2 (en) 2021-04-29
AU2021209196B2 (en) 2023-02-02
CN106536540A (zh) 2017-03-22
WO2016014360A1 (en) 2016-01-28
RU2021106673A (ru) 2021-11-25
AU2021209196A1 (en) 2021-08-19
EP3172219A4 (en) 2018-04-04
KR20170028435A (ko) 2017-03-13
IL250148B (en) 2022-11-01
US20170209593A1 (en) 2017-07-27
CA2955007C (en) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2017011281A (es) Conjugados de amatoxina y anticuerpos.
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2019003796A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas.
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
DOP2023000150A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
EP3411074A4 (en) SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHOD FOR THE PRODUCTION AND USE THEREOF OF SUCH CONJUGATES
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MX386692B (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos
MX2015015239A (es) Composiciones y metodos.
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
MX2019004434A (es) Anticuerpos anti-edb y conjugados anticuerpo-fármaco.
AU201613942S (en) Lamp
PL3411076T3 (pl) Koniugaty przeciwciało-lek ukierunkowane na uparap
AU351658S (en) Keyboard
GT201200244A (es) Procedimiento de activación y conjugación de biomoléculas
BR112018012524A2 (pt) anticorpos variantes para conjugação sítio-específica
BR112017001403A2 (pt) métodos para conjugar um agente com uma fração de tiol em uma proteína que contém pelo menos uma ligação trissulfeto
AU201712970S (en) Vehicle gate component
AU201712955S (en) Vehicle gate component
AU201712972S (en) Vehicle gate component
AU201714577S (en) Conveyor chain link
AU201710932S (en) Lamp
AU201614976S (en) Lamp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal